By vgreene, 19 January, 2021 Vaccine providers should be trained to observe pts after COVID 19 vaccination to monitor for occurrence of immediate adverse rxns Those w a hx of immediate allergic rxn of any severity to a vaccine or injectable tx or persons w hx of anaphylaxis due to an
By vgreene, 19 January, 2021 Neither of the mRNA vaccines contains eggs gelatin latex or preservatives
By vgreene, 19 January, 2021 There is no contraindication precaution to vaccination for pts w hx of allergies that are unrelated to components of the mRNA vaccines other vaccines injectable therapies or polysorbate This includes allergies to PO med incl the PO equivalents of injectab
By vgreene, 19 January, 2021 In Pfizer BioNTech clinical trials potential allergic rxns occurred in 0 63 of vaccine recipients vs 0 51 of placebo In the Moderna trials the rates were 1 5 of vaccine recipients vs 1 1 of placebo
By vgreene, 19 January, 2021 Hx of any immediate allergic rxn to vaccines or injectable tx except those related to mRNA vaccine components or polysorbate as these are contraindications Action Perform risk assessment consider deferral of vaccination and or referral to allergy immunolo
By vgreene, 19 January, 2021 Moderate severe acute illness Action Perform risk assessment consider potential deferral of vaccination observe for 15min if decide to vaccinate
By vgreene, 19 January, 2021 Note Previous hx of COVID 19 symptomatic or asymptomatic is not a contraindication to vaccination although CDC recommends that symptomatic pts defer vaccination until they are recovered out of isolation
By vgreene, 19 January, 2021 Individuals w an immediate allergic rxn to the 1st dose of an mRNA vaccine should not receive additional doses of either mRNA vaccine Providers should try to determine whether rxns are immediate allergic rxns or other types of common rxns vasovagal post v
